Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

This study has been completed.
Information provided by:
Bristol-Myers Squibb Identifier:
First received: February 9, 2006
Last updated: February 27, 2010
Last verified: January 2009
The purpose of this clinical research study is to compare the best overall response rate (BORR)(as per modified WHO criteria) in patients with previously treated, therapy-refractory, or -intolerant, Stage III (unresectable) or Stage IV melanoma receiving ipilimumab doses of 0.3, 3, and 10 mg/kg. The safety of this product will also be evaluated.

Condition Intervention Phase
Drug: ipilimumab (MDX-010, BMS-734016)
Drug: Ipilimumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Multi-center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • estimate BORR in patients with previously treated, therapy-refractory or -intolerant, Stage III (unresectable) or Stage IV melanoma receiving ipilimumab doses of 0.3, 3, and 10 mg/kg.

Secondary Outcome Measures:
  • estimate progression free survival rate at Week 12 assessment and other timepoints
  • estimate disease control rate at various time points
  • estimate overall survival
  • estimate survival rate at one year
  • evaluate health-related quality of life
  • obtain pharmacokinetic samples for population PK analysis

Estimated Enrollment: 210
Study Start Date: April 2006
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: ipilimumab (MDX-010, BMS-734016)
IV solution, IV, 0.3mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
Experimental: 2 Drug: Ipilimumab
IV solution, IV, 3 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
Experimental: 3 Drug: Ipilimumab
IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.


Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with previously treated, therapy-refractory or -intolerant, Stage III (unresectable) or Stage IV melanoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00289640

  Hide Study Locations
United States, Arizona
Arizona Cancer Center
Tucson, Arizona, United States, 85724
United States, California
Wilshire Oncology Medical Group Inc
Laverne, California, United States, 91750
Scripps Cancer Center
San Diego, California, United States, 92121
The Angeles Clinic And Research Institution
Santa Monica, California, United States, 90404
United States, Connecticut
Yale University School Of Medicine
New Haven, Connecticut, United States, 06520
United States, Florida
Baptist Cancer Institute
Jacksonville, Florida, United States, 32207
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States, 33140
Md Anderson Cancer Center Orlando
Orlando, Florida, United States, 32806
Palm Beach Cancer Institute
West Palm Beach, Florida, United States, 33401
United States, Illinois
Oncology Specialists, Sc
Park Ridge, Illinois, United States, 60068
United States, Indiana
American Health Network
Indianapolis, Indiana, United States, 46202
United States, Kentucky
University Of Louisville
Louisville, Kentucky, United States, 40202
United States, Maryland
Harry And Jeanette Weinberg Cancer Inst At Franklin Square
Baltimore, Maryland, United States, 21237
United States, Minnesota
Hubert H. Humphrey Cancer Center
Robbinsdale, Minnesota, United States, 55422
United States, Missouri
Ellis Fischel Cancer Center
Columbia, Missouri, United States, 65203
St Joseph Oncology Inc
St Joseph, Missouri, United States, 64507
Washington University School Of Medicine
St. Louis, Missouri, United States, 63110
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021
United States, North Carolina
Presbyterian Hospital
Charlotte, North Carolina, United States, 28204
United States, Ohio
The Christ Hospital Cancer Center Research
Cincinnati, Ohio, United States, 45219
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Oregon
Providence Portland Medical Center
Portland, Oregon, United States, 97213
United States, South Carolina
Cancer Centers Of The Carolinas
Greenville, South Carolina, United States, 29615
United States, Texas
Center For Oncology Research & Treatment, P.A.
Dallas, Texas, United States, 75230
Mary Crowley Medical Research Center
Dallas, Texas, United States, 75246
Australia, New South Wales
Local Institution
Newcastle, New South Wales, Australia, 2300
Australia, Queensland
Local Institution
Brisbane, Queensland, Australia, 4101
Australia, Victoria
Local Institution
Heidelberg, Victoria, Australia, 3084
Local Institution
Wodonga, Victoria, Australia, 3690
Local Institution
Brussels, Belgium, 1090
Local Institution
Bruxelles, Belgium, 1200
Local Institution
Bruxelles, Belgium, 1070
Local Institution
Centro-Porto Alegre, Rio Grande Do Sul, Brazil, 90020
Local Institution
Porto Alegre, Rio Grande Do Sul, Brazil, 90610
Local Institution
Jau, Sao Paulo, Brazil, 17210
Local Institution
Sao Paulo, Brazil, 01509
Canada, Alberta
Local Institution
Calgary, Alberta, Canada, T2N 4N2
Local Institution
Edmonton, Alberta, Canada, T6G 1Z2
Canada, Ontario
Local Institution
Kingston, Ontario, Canada, K7L 5P9
Czech Republic
Local Institution
Olomouc, Czech Republic, 775 20
Local Institution
Praha, Czech Republic, 128 08
Local Institution
Brest, Cedex, France, 29200
Local Institution
Clermont Ferrand, France, 63058
Local Institution
Lyon, France, 69288
Local Institution
Lyon Cedex 08, France, 69373
Local Institution
Marseille Cedex 09, France, 13009
Local Institution
Paris, France, 75010
Local Institution
Rennes, France, 35042
Local Institution
Toulouse, France, 31059
Local Institution
Vandoeuvre Les Nancy, France, 54511
Local Institution
Berlin, Germany, 12200
Local Institution
Essen, Germany, 45122
Local Institution
Heidelberg, Germany, 69115
Local Institution
Jena, Germany, 07740
Local Institution
Kiel, Germany, 24105
Local Institution
Mannheim, Germany, 68169
Local Institution
Wurzburg, Germany, 97080
Local Institution
Pécs, Hungary, 7624
South Africa
Local Institution
Johannesburg, Gauteng, South Africa, 2199
Local Institution
Pretoria, Gauteng, South Africa, 0041
Local Institution
Pretoria, Gauteng, South Africa, 0181
Local Institution
Cape Town, Western Cape, South Africa, 7506
Sponsors and Collaborators
Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided by Bristol-Myers Squibb

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Study Director, Bristol-Myers Squibb Identifier: NCT00289640     History of Changes
Other Study ID Numbers: CA184-022
Study First Received: February 9, 2006
Last Updated: February 27, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:
Stage III (unresectable)
Stage IV melanoma

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Antibodies, Monoclonal
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs processed this record on November 27, 2015